Gefurulimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Gefurulimab
- alxn 1720
- ALXN-1720
- alxn1720
- ALXN1720
- ALXN1720 IV
- gefurulimab
- Gefurulimab
- gefurulimab [INN]
- GEFURULIMAB [USAN]
- Gefurulimab [WHO-DD]
- gefurulimab inn
- gefurulimab usan
- gefurulimab who dd
- immunoglobulin bispecific anti human serum albumin human lama glama monoclonal alxn1720 single domain vhh fragment fusion protein with peptide linker synthetic 15 amino acid fusion protein with anti human complement c5 human lama glama monoclonal alxn1720 single domain vhh fragment
- IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN SERUM ALBUMIN) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (SYNTHETIC 15 AMINO-ACID) FUSION PROTEIN WITH ANTI-(HUMAN COMPLEMENT C5) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT)
- CAS registry numbers
- 2456407-94-4
- ChEMBL ID
- CHEMBL5095307
- FDA ingredient codes (UNII)
- 6PWU78BV6C
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -mab
- Condition
- Myasthenia Gravis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004991
- Subject identifier
- D009157
- Condition
- Proteinuria
- Highest recorded phase
- 1
- Condition identifier
- HP:0000093
- Subject identifier
- D011507
- Condition identifier
- EFO_0004991
- Highest recorded phase
- 3
- Condition identifier
- HP_0000093
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009688
- Highest recorded phase
- 3
- NCT05314231
- NCT05556096
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Disulfide bridges
- Sequence
- 22-95 $ 160-234
- Component
- Sequence
- Type
- Protein
- Sequence
- EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGAGGGGAGGGGSEVQLVESGGGLVQPGGSLRLSCAASGRAHSDYAMAWFRQAPGQEREFVAGIGWSGGDTLYADSVRGRFTNSRDNSKNTLYLQMNSLRAEDTAVYYCAARQGQYIYSSMRSDSYDYWGQGTLVTVSS
Related records
Trials (6)
- A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants
- PK Study of Gefurulimab SC in Healthy Chinese Adult Participants
- PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
- Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
- Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
- Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
In development for (2)
- Myasthenia gravis Phase 3
- Proteinuria Phase 1